Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 10INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Urogenital Neoplasms 1Thymoma 1Stomach Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Liver Neoplasms 1Genital Neoplasms, Female 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Advanced Primary Liver Cancer 1Adrenocortical Carcinoma 1

Interventions

Oxaliplatin 10Fluorouracil 6Irinotecan 5Docetaxel 5Capecitabine 5tislelizumab 4S 1 (combination) 4Paclitaxel 4Endoscopic Mucosal Resection 4XELOX 3Levoleucovorin 3Laparoscopy 3Folfox protocol 3sintilimab 2apatinib 2Proton Pump Inhibitors 2Gastroenterostomy 2Gastrectomy 2Clarithromycin 2Chemotherapy, Adjuvant 2Amoxicillin 2vactosertib 1titanium silicide 1pembrolizumab 1lenvatinib 1durvalumab 1bismuth tripotassium dicitrate 1anlotinib 1Trastuzumab 1Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Stomach Neoplasms × lenvatinib × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡